Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Dr. Pothuri on Treatment Considerations for PARP Inhibitors in Ovarian Cancer

July 12th 2021

Bhavana Pothuri, MD, discusses treatment considerations for PARP inhibitors in patients with ovarian cancer.

Galinpepimut-S Plus Pembrolizumab Shows Early Activity in Advanced Ovarian Cancer

July 9th 2021

The combination of galinpepimut-S and pembrolizumab has demonstrated promising clinical immunobiological activity in patients with Wilms Tumor 1–positive, relapsed or refractory, platinum-resistant advanced metastatic ovarian cancer, according to results from an ad-hoc analysis of a phase 1/2 trial.

Dr. O’Malley on the Efficacy of Pembrolizumab in Advanced Ovarian Cancer

July 8th 2021

David M. O'Malley, MD, discusses the efficacy of pembrolizumab in patients with advanced ovarian cancer.

Research Reflections: O'Malley Relays Key Updates in Ovarian and Endometrial Cancers

July 5th 2021

Dr. O’Malley discusses key findings from 6 trials that were presented at the virtual 2021 SGO Annual Meeting on Women’s Cancer.

Dr. Monk on the Mechanism of Action of VB-111 in Ovarian Cancer

June 18th 2021

Bradley Monk, MD, FACOG, FACS, discusses the mechanism of action of VB-111 in patients with ovarian cancer.

Dr. Pothuri on the Role of Maintenance Therapy in BRCA+ Ovarian Cancer

June 11th 2021

Bhavana Pothuri, MD, discusses the role of maintenance therapy in BRCA-positive ovarian cancer.

Maintenance Olaparib/Bevacizumab Provides Substantial PFS, PFS2 Benefit in HRD+ Ovarian Cancer, Irrespective of Disease Stage

June 8th 2021

The addition of olaparib to bevacizumab provided a substantial progression-free survival (PFS) and second PFS benefit over bevacizumab alone in the maintenance treatment of patients with homologous recombination deficiency–positive, newly diagnosed advanced ovarian cancer, regardless of International Federation of Gynecology and Obstetrics disease stage.

Mirvetuximab Soravtansine Plus Bevacizumab May Provide an Effective Non-Platinum Option in Recurrent, Platinum Agnostic Ovarian Cancer

June 7th 2021

Mirvetuximab soravtansine in combination with bevacizumab yielded durable responses in patients with recurrent, platinum agnostic ovarian cancer, a population in need of more effective, non-platinum treatments.

Niraparib Individualized Starting Dose Tolerable in Platinum-Sensitive Recurrent Ovarian Cancer

June 5th 2021

Niraparib, when delivered at an individualized starting dose, was found to be well tolerated in patients with platinum-sensitive recurrent ovarian cancer.

Dr. Chern on Future Research Directions in Ovarian Cancer

May 25th 2021

Jing-Yi Chern, MD, ScM, discusses future research directions in the treatment of patients with ovarian cancer.

FDA Grants Breakthrough Therapy Designation to VS-6766/Defactinib for Recurrent Low-Grade Serous Ovarian Cancer

May 24th 2021

The FDA has granted a breakthrough therapy designation to VS-6766 plus defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer, irrespective of KRAS status, following 1 or more previous lines of therapy, including platinum-based chemotherapy

Dr. Monk on Guidelines for Maintenance PARP Inhibitors in Ovarian Cancer

May 19th 2021

Bradley J. Monk, MD, FACS, FACOG, highlights current guidelines for utilizing maintenance PARP inhibitors in the treatment of patients with ovarian cancer.

Molecular Markers and Prior Treatment Inform Maintenance PARP Inhibition in Ovarian Cancer

May 11th 2021

Bradley J. Monk, MD, FACOG, FACS, discusses findings from key studies that solidified the role of PARP inhibition as maintenance therapy for patients with ovarian cancer, as well as guidelines for selecting PARP inhibitors alone or in combination with bevacizumab.

ARIEL2 Analysis Sheds Light on Biomarkers of Response to Rucaparib in Ovarian Cancer

May 4th 2021

RAD51C and RAD51D mutations and high-level BRCA1 promotor methylation are predictive of response to rucaparib in patients with recurrent ovarian cancer, while genomic scars linked with homologous recombination deficiency is predictive of response only in those with platinum-sensitive disease.

Dr. Miller on the Potential Utility of Sequential PARP Inhibition in Ovarian Cancer

April 27th 2021

Eirwen M. Miller, MD, discusses the potential utility of sequential PARP inhibition in ovarian cancer.

Bringing Individualized Care to Patients With Breast and Ovarian Cancers in the Caribbean

April 26th 2021

Current breast cancer screening practices in the Caribbean exclude the majority of the younger patient population, thereby leaving many cases of breast cancer undiagnosed.

Unique Landscape of Actionable Pathogenic Variants Unfolds in Breast and Ovarian Cancers in the Caribbean

April 16th 2021

Sophia George, PhD, and Judith E. Hurley, MD, discuss the importance of the genetic association study, challenges faced with launching such an effort, the key findings from the research, and the clinical implications of the data in the Caribbean as well as the United States

Pursuing PARP Beyond HRD+ Ovarian Cancer

April 9th 2021

Hye Sook Chon, MD, teases out some of the differences between the data with PARP inhibitors in the frontline maintenance setting and shed light on ongoing research with combinations that could broaden their utility in patients with advanced ovarian cancer.

Utility of HRD Testing in Ovarian Cancer Expands, but Standardization Remains Elusive

April 6th 2021

Thomas C. Krivak, MD, discusses the significance of HRD in ovarian cancer, approved and prospective HRD tests, and considerations for genomic testing in this population.

Dr. Nakayama on Using Precision Medicine With Mirvetuximab Soravtansine in Ovarian Cancer

April 5th 2021

John Nakayama, MD, discusses the potential utility of precision medicine with mirvetuximab soravtansine in ovarian cancer.